Patients and methods
In a phase III (a/b) clinical trial, patients with primary axillary HH were asked to complete the HidroQoL at several timepoints (baseline, after 4, 8, 12, 28, 52, and 72 weeks). This clinical trial investigated the effects of a topical cream containing 1% glycopyrronium bromide for which safety and efficiency was reported recently [Data from this clinical trial (phase III a) have already been used for previous validation analyses [